Zimmer Biomet Holdings (ZBH): Sales Miss Was Disappointing But Now Its In The Stock - Leerink
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Needham & Company Upgrades Zimmer Biomet (ZBH) to Strong Buy; Supply Issues Only Temporary
November 1, 2016 7:24 AM EDTNeedham & Company upgraded Zimmer Biomet (NYSE: ZBH) from Buy to Strong Buy with a price target of $148.00 (from $150.00), saying supply issues are only temporary.
Analyst Mike Matson commented, " ZBH missed consensus revenue and met consensus EPS in 3Q16 and management lowered its 2016 guidance.... More